The Siasat | 15/11/2020 03:55 PM | Click to read full article
To suppress the impact of lung fibrosis, concerning COVID patients, scientists have been developing new treatment therapies, targeting the complications developed by the mutual relationship between the two. The first of the Purdue team’s novel targeted molecules are designed to slow fibrosis and extend life. The second IPF therapy suppresses fibrosis-inducing cytokine production.
The two therapies will be moving into human clinical trials within the next several months.